Clinical TrialCompleted

Clinical Study of Esketamine for Improving Depressive Symptoms in Patients With Lung Cancer After Smoking Cessation

Parallel-group controlled trial of intranasal esketamine (0.5 mg/kg) vs saline placebo in lung-cancer surgery patients with a long smoking history (≥20/day × 5+ years) undergoing smoking cessation. Target: 80 participants (40/40). Primary outcomes: HDRS-24, MADRS, CADSS, BPRS. Sponsor: Zhejiang Provincial People's Hospital, Hangzhou, China.

Target Enrollment
80 participants
Study Type
interventional
Design
Randomized, double Blind

Study Details

  • Status
    Completed
  • Type
    interventional
  • Design
    Randomizeddouble Blind
  • Target Enrollment80 participants
  • Timeline
    Start: 2023-02-24

Related Publications

Efficacy and safety of esketamine for smoking cessation among patients diagnosed with lung cancer and major depression disorder: A randomized, placebo-controlled clinical trial

Published
Authors
Hong, C. J.

Your Library